Ostarine (MK-2866)

Ostarine selectively binds androgen receptors in muscle and bone tissue with high affinity. It stimulates anabolic pathways that promote protein synthesis, nitrogen retention, and lean mass accrual while demonstrating minimal activity in the prostate, skin, and other androgen-sensitive tissues. In clinical settings, it has demonstrated the ability to preserve and increase lean body mass even in patients experiencing muscle wasting from cancer or aging. Its tissue selectivity ratio is approximately 10:1 (anabolic to androgenic).

Ostarine has high oral bioavailability (estimated >95% in preclinical models). Peak plasma concentration occurs at approximately 1-2 hours. The terminal half-life is approximately 24 hours, supporting once-daily dosing. Steady state is reached within 7-10 days. Metabolism is hepatic, primarily via CYP3A4, but the compound is non-methylated and has minimal liver toxicity. Clinical trials showed no significant elevations in liver enzymes at therapeutic doses.

• ✓Preservation of lean mass during caloric deficit (primary use case)
• ✓Moderate lean mass gains (2-5 lbs in 8 weeks on a slight surplus)
• ✓Enhanced muscle hardness and definition during cutting
• ✓Improved recovery and reduced delayed onset muscle soreness
• ✓Joint healing properties (anecdotally reported, supported by connective tissue data)
• ✓Does not aromatize; no estrogenic side effects
• ✓Mild side effect profile compared to all other SARMs
• ✓Extensive human safety data from clinical trials
• ✓Improved bone mineral density

• ⚠Mild testosterone suppression (dose-dependent; less severe than LGD-4033 or RAD-140)
• ⚠Mild HDL suppression (typically 10-20%)
• ⚠Potential mild headaches in the first few days
• ⚠Slight lethargy at higher doses (20-25 mg) toward the end of an 8-week cycle
• ⚠Rarely: mild back acne or skin oiliness
• ⚠Temporary reduction in SHBG
• ⚠All side effects are reversible upon discontinuation

Contraindications

• 🚫Hormone-sensitive cancers
• 🚫Pregnant or breastfeeding women
• 🚫Individuals under 21 years of age
• 🚫Pre-existing severe lipid dysfunction
• 🚫Concurrent use of other hormonal therapies without medical oversight

**PCT may or may not be required** depending on dose and duration. **Low dose / short cycle (10-15 mg for 6-8 weeks):** - Many users recover naturally within 3-4 weeks without PCT - Recommended: get bloodwork at 3 weeks post-cycle; if testosterone is still significantly suppressed, begin Nolvadex **Higher dose / longer cycle (20-25 mg for 8-12 weeks):** - Nolvadex 20 mg/day for 3-4 weeks is recommended as a precautionary PCT **Assessment approach:** - Get bloodwork 2-3 weeks after last dose - If testosterone is >300 ng/dL and you feel fine, PCT may be unnecessary - If testosterone is below 300 ng/dL or you have symptoms, run Nolvadex 20 mg/day for 4 weeks

• 1.Ostarine is the gold standard "first SARM cycle" for a reason: reliable, predictable, well-studied
• 2.It truly shines during a cut; if you want to bulk, consider LGD-4033 instead
• 3.Joint improvement is a real and notable benefit; many users report less knee and shoulder discomfort
• 4.Don't expect dramatic mass gains; Ostarine is about preserving muscle and improving body composition
• 5.It stacks beautifully with Cardarine for a cutting cycle or with MK-677 for a lean bulk
• 6.If you are in a caloric surplus, expect 2-3 lbs of actual lean tissue gain over 8 weeks
• 7.If you are cutting at a moderate deficit (-500 kcal), expect to maintain all your muscle while losing fat
• 8.Liquid Ostarine has a mild chemical taste; much more tolerable than RAD-140

1. [1]Dalton JT, et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women. J Cachexia Sarcopenia Muscle.
2. [2]Dobs AS, et al. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer. Lancet Oncol.